Nonalcoholic Steatohepatitis (NASH) Market by Therapeutics | 2020
NASH Market is expected to garner $1.6 billion by 2020, registering a CAGR of 25.6% during the forecast period 2014-2020. Increase in cycles of clinical trials and their success rate has increased the probability of industries receiving commercial approval for NASH therapeutics by the end of 2017. NASH Market is expected to garner $1.6 billion by 2020, registering a CAGR of 25.6% during the forecast period 2014-2020. Increase in cycles of clinical trials and their success rate has increased the probability of industries receiving commercial approval for NASH therapeutics by the end of 2017.
Introductionof Nonalcoholic Steatohepatitis (NASH) Market The global market is expected to garner $1.6 billion by 2020, registering a CAGR of 25.6% during the period 2014-2020. The high prevalence of Type II diabetes and obesity, which lead to NASH and other nonalcoholic fatty liver diseases (NAFLD), would boost market growth. North America's heightened focus of NASH research has resulted in its accounting for nearly half of the global market. It is also the region with the maximum occurrences of NASH and other nonalcoholic fatty liver diseases. Europe ranks second in terms of the prevalence of NASH. The number of patients living with the diabetes worldwide is expected to soar from 371 million in 2012 to 552 million by 2030. This suggests that by 2030, there will be 3 new cases of diabetes every 10 seconds. "The rampant growth of diabetes and obesity has prompted pharmaceutical manufacturers to seek out novel pharmaceutical solutions to tap promising potential in NASH," states AMR analyst Roshan Deshmukh. "Instrumental initiatives and increasing clinical trials for the development of novel NASH therapeutics will steer its faster commercialization," adds the analyst.
Introductionof Nonalcoholic Steatohepatitis (NASH) Market Scope of the Report Key Benefits Key Audiences
- Page 1: Nonalcoholic Steatohepatitis (NASH)
- Page 5 and 6: Table of Content (TOC) Chapter 1: I
- Page 7 and 8: Segments Nonalcoholic Steatohepatit
- Page 9: Thank You Ceramic Matrix Composites
Introductionof<br />
<strong>Nonalcoholic</strong> <strong>Steatohepatitis</strong> (<strong>NASH</strong>) <strong>Market</strong><br />
The global market is expected to garner $1.6 billion <strong>by</strong> <strong>2020</strong>, registering a CAGR of<br />
25.6% during the period 2014-<strong>2020</strong>. The high prevalence of Type II diabetes and<br />
obesity, which lead to <strong>NASH</strong> and other nonalcoholic fatty liver diseases (NAFLD), would<br />
boost market growth. North America's heightened focus of <strong>NASH</strong> research has<br />
resulted in its accounting for nearly half of the global market. It is also the region with<br />
the maximum occurrences of <strong>NASH</strong> and other nonalcoholic fatty liver diseases. Europe<br />
ranks second in terms of the prevalence of <strong>NASH</strong>.<br />
The number of patients living with the diabetes worldwide is expected to soar from<br />
371 million in 2012 to 552 million <strong>by</strong> 2030. This suggests that <strong>by</strong> 2030, there will be 3<br />
new cases of diabetes every 10 seconds. "The rampant growth of diabetes and obesity<br />
has prompted pharmaceutical manufacturers to seek out novel pharmaceutical<br />
solutions to tap promising potential in <strong>NASH</strong>," states AMR analyst Roshan Deshmukh.<br />
"Instrumental initiatives and increasing clinical trials for the development of novel<br />
<strong>NASH</strong> therapeutics will steer its faster commercialization," adds the analyst.
Change language